CR9626A - Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato - Google Patents
Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinatoInfo
- Publication number
- CR9626A CR9626A CR9626A CR9626A CR9626A CR 9626 A CR9626 A CR 9626A CR 9626 A CR9626 A CR 9626A CR 9626 A CR9626 A CR 9626A CR 9626 A CR9626 A CR 9626A
- Authority
- CR
- Costa Rica
- Prior art keywords
- oral
- succinate
- desmetilvenlafaxin
- dosage
- ways
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe una forma de dosificacion unitaria altamente biodisponible, oral de O-desmetilvenlafaxina succinato (DVS) que tiene una sostenida durante multiples horas para proporcionar una liberacion total de mas de alrededor de 85% dentro de aproximadamente 12 a aproximadamente 14 horas; en una modalidad, la composicion DVS superbiodisponible tiene una liberacion retardada de alrededor de 2 horas y una liberacion total de mas de alrededor de 95% durante 12 a aproximadamente 14 horas; tambien se describe el uso de la formulacion para tratar depresion y reducir efectos secundarios gastrointestinales de O-desmetilvenlafaxina (ODV).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69962305P | 2005-07-15 | 2005-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9626A true CR9626A (es) | 2008-04-10 |
Family
ID=37669348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9626A CR9626A (es) | 2005-07-15 | 2007-12-20 | Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato |
Country Status (20)
Country | Link |
---|---|
US (1) | US20070014859A1 (es) |
EP (1) | EP1904040A2 (es) |
JP (1) | JP2009501233A (es) |
KR (1) | KR20080025405A (es) |
CN (1) | CN101247791A (es) |
AR (1) | AR054833A1 (es) |
AU (1) | AU2006270315A1 (es) |
BR (1) | BRPI0613484A2 (es) |
CA (1) | CA2612960A1 (es) |
CR (1) | CR9626A (es) |
EC (1) | ECSP088106A (es) |
GT (1) | GT200600307A (es) |
IL (1) | IL188313A0 (es) |
MX (1) | MX2008000666A (es) |
NO (1) | NO20080088L (es) |
PE (1) | PE20070192A1 (es) |
RU (1) | RU2007148195A (es) |
SV (1) | SV2008002612A (es) |
TW (1) | TW200740427A (es) |
WO (1) | WO2007011619A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
EP1863464B1 (en) * | 2005-03-31 | 2009-11-11 | Wyeth | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
US20080175873A1 (en) * | 2005-06-02 | 2008-07-24 | Biovail Laboratories International S.R.L. | Modified release composition of at least one form of venlafaxine |
AR057854A1 (es) | 2005-11-04 | 2007-12-19 | Wyeth Corp | Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida |
WO2007067501A1 (en) * | 2005-12-05 | 2007-06-14 | Wyeth | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols |
TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
CA2692738A1 (en) * | 2007-07-12 | 2009-01-15 | Dr. Reddy's Laboratories, Ltd. | O-desmethylvenlafaxine |
CA2702664A1 (en) * | 2007-10-16 | 2009-04-23 | Alphapharm Pty Ltd | Controlled-release pharmaceutical formulation |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
US20110027324A1 (en) * | 2007-12-10 | 2011-02-03 | Wyeth Llc | O-desmethyl-venlafaxine for treating major depressive disorder |
EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
JP5681108B2 (ja) | 2008-08-04 | 2015-03-04 | ワイス・エルエルシー | 4−アニリノ−3−シアノキノリンとカペシタビンの抗新生物薬の組合せ |
CN101716168B (zh) * | 2008-10-09 | 2014-09-17 | 北京德众万全医药科技有限公司 | 一种含有去甲文拉法新的盐的药物组合物及其制备方法 |
EP2191822A1 (en) * | 2008-11-26 | 2010-06-02 | LEK Pharmaceuticals d.d. | Controlled release pharmaceutical compositions comprising O-desmethyl-venlafaxine |
RU2011139363A (ru) | 2009-04-06 | 2013-05-20 | ВАЙЕТ ЭлЭлСи | Схема лечения рака молочной железы с использованием нератиниба |
CA2780332C (en) * | 2009-11-09 | 2018-01-30 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
US9408814B2 (en) | 2010-03-31 | 2016-08-09 | Wockhardt Limited | Modified release dosage form comprising desvenlafaxine or salts thereof |
CN102085197B (zh) * | 2010-12-14 | 2013-08-14 | 北京万生药业有限责任公司 | 一种文拉法辛缓释制剂及其制备方法 |
MX2013011884A (es) | 2011-04-12 | 2013-11-21 | Lupin Ltd | Composiciones farmaceuticas de liberacion modificada de desvenlafaxina. |
CN111008356B (zh) * | 2019-11-13 | 2023-06-16 | 成都理工大学 | 一种基于WTSVD算法扣除背景的γ能谱集分析方法 |
CN114288273B (zh) * | 2022-02-11 | 2022-10-18 | 桂林华信制药有限公司 | 一种盐酸文拉法辛缓释胶囊及其生产工艺 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
WO2000076955A1 (en) * | 1999-06-15 | 2000-12-21 | American Home Products Corporation | Enantiomers of o-desmethyl venlafaxine |
AR021347A1 (es) * | 1999-10-20 | 2002-07-17 | Cipla Ltd | Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma |
WO2003082262A2 (en) * | 2002-03-28 | 2003-10-09 | Synthon B.V. | Compositions of venlafaxine base |
US6703044B1 (en) * | 2002-10-25 | 2004-03-09 | Dexcel Pharma Tech, Ltd | Venlafaxine formulations |
ES2277030T3 (es) * | 2003-05-02 | 2007-07-01 | Dexcel Ltd. | Formulacion en comprimidos de venlafaxina de liberacion prolongada. |
BRPI0507372A (pt) * | 2004-02-06 | 2007-07-10 | Wyeth Corp | formulação de multiparticulados de um o-desmetilvenlafaxina (odv), métodos para tratar de depressão em um paciente em sua necessidade e para reduzir os efeitos colaterais gastrintestinais da venlafaxina em um paciente, formulação de liberação modificada de um multiparticulado, método para reduzir os efeitos colaterais gastrintestinais de um odv em um paciente, produto de venlafaxina de liberação modificada, métodos para reduzir os efeitos colaterais gastrintestinais associados com o tratamento da venlafaxina e para liberar odv a um paciente pediátrico ou geriátrico, formulações de multiparticulados de formiato ou succinato de odv e de liberação retardada de formiato ou succinato de odv, uso de uma formulação, e, pacote farmacêutico |
US8394409B2 (en) * | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
-
2006
- 2006-07-13 EP EP06787061A patent/EP1904040A2/en not_active Withdrawn
- 2006-07-13 AU AU2006270315A patent/AU2006270315A1/en not_active Abandoned
- 2006-07-13 PE PE2006000833A patent/PE20070192A1/es not_active Application Discontinuation
- 2006-07-13 RU RU2007148195/15A patent/RU2007148195A/ru unknown
- 2006-07-13 CA CA002612960A patent/CA2612960A1/en not_active Abandoned
- 2006-07-13 US US11/486,324 patent/US20070014859A1/en not_active Abandoned
- 2006-07-13 GT GT200600307A patent/GT200600307A/es unknown
- 2006-07-13 TW TW095125660A patent/TW200740427A/zh unknown
- 2006-07-13 WO PCT/US2006/027106 patent/WO2007011619A2/en active Application Filing
- 2006-07-13 SV SV2006002612A patent/SV2008002612A/es unknown
- 2006-07-13 JP JP2008521581A patent/JP2009501233A/ja not_active Withdrawn
- 2006-07-13 BR BRPI0613484A patent/BRPI0613484A2/pt not_active IP Right Cessation
- 2006-07-13 AR ARP060103012A patent/AR054833A1/es unknown
- 2006-07-13 MX MX2008000666A patent/MX2008000666A/es not_active Application Discontinuation
- 2006-07-13 KR KR1020087001067A patent/KR20080025405A/ko not_active Application Discontinuation
- 2006-07-13 CN CNA2006800258002A patent/CN101247791A/zh active Pending
-
2007
- 2007-12-20 IL IL188313A patent/IL188313A0/en unknown
- 2007-12-20 CR CR9626A patent/CR9626A/es not_active Application Discontinuation
-
2008
- 2008-01-07 NO NO20080088A patent/NO20080088L/no not_active Application Discontinuation
- 2008-01-14 EC EC2008008106A patent/ECSP088106A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR054833A1 (es) | 2007-07-18 |
KR20080025405A (ko) | 2008-03-20 |
EP1904040A2 (en) | 2008-04-02 |
WO2007011619A3 (en) | 2007-06-21 |
CN101247791A (zh) | 2008-08-20 |
PE20070192A1 (es) | 2007-03-16 |
CA2612960A1 (en) | 2007-01-25 |
JP2009501233A (ja) | 2009-01-15 |
ECSP088106A (es) | 2008-02-20 |
RU2007148195A (ru) | 2009-08-20 |
MX2008000666A (es) | 2008-03-13 |
IL188313A0 (en) | 2008-04-13 |
BRPI0613484A2 (pt) | 2016-11-16 |
AU2006270315A1 (en) | 2007-01-25 |
GT200600307A (es) | 2008-04-24 |
SV2008002612A (es) | 2008-08-29 |
TW200740427A (en) | 2007-11-01 |
WO2007011619A2 (en) | 2007-01-25 |
NO20080088L (no) | 2008-04-02 |
US20070014859A1 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9626A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponible de un o-desmetilvenlafaxin succinato | |
ES2502472T3 (es) | Composición adhesiva para su uso en un inmunosensor | |
ES2487496T3 (es) | Agente para aliviar el síndrome metabólico | |
ES2525320T3 (es) | Composiciones de calentamiento y sistemas para su descarga | |
ES2540751T3 (es) | Composición para mejorar la función sexual masculina que contiene extracto de baya de ginseng | |
AR115939A2 (es) | Composición que contiene palmitoil-etanolamida ultra-micronizada | |
ES2602986T3 (es) | Nuevas composiciones cosméticas y/o farmacológicas y sus aplicaciones | |
CL2010000516A1 (es) | Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07). | |
AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
CL2008000893A1 (es) | Composición para el cuidado bucal que comprende una cantidad efectiva de un aminoácido básico y un agente antibacteriano; uso en el tratamiento antibacteriano de la cavidad bucal. | |
ECSP077999A (es) | Formulaciones de una sal de bupropion de liberación modificada | |
ECSP13012546A (es) | Formulación tópica para un inhibidor de jak | |
ES2556585T3 (es) | Composiciones que comprenden sulfato de salbutamol | |
UY27740A1 (es) | Nuevos compuestos | |
ES2478264T3 (es) | Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica | |
ES2422556T3 (es) | Tratamiento de hepatitis vírica | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
CO6290631A2 (es) | Composición oral que contiene amino ácidos y un agente blanqueador | |
CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
AR070356A1 (es) | Producto para cuidado oral y metodos de uso del mismo | |
CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
ECSP088889A (es) | Forma nueva de administración de racecadotril | |
PE20080400A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
BRPI0620229A8 (pt) | formulação | |
CL2012000392A1 (es) | Uso de un anticuerpo anti-cd20 afucosilado con una cantidad de fucosa de 60% o menos para tratar cancer en combinacion con fludarabina . |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |